drugset / Trial / NCT05520970
Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The immunogenicity and safety profiles of AdCLD-CoV19-1 (5.0×10\^10 VP/dose) will be assessed for 1-dose or 2-dose regimen in SARS-CoV-2 seronegative healthy adults.
Timeline
- Start
- 2022-08-19
- Primary completion
- 2022-11-08
- Completion
- 2022-11-08
Outcome
Outcome not reported
Stopped: “Study early terminated based on the sponsor(manufacture)'s decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AdCLD-CoV19-1 | Vaccine | 5e+10 unknown | Intramuscular |